Barclays CEO C.S. Venkatakrishnan is remission from cancer four months after being diagnosed with Non-Hodgkin Lymphoma and stepping back from his position to focus on treatment, Financial News’ Paul Clarke reports. Reference Link
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on BCS:
- Barclays price target raised to 240 GBp from 230 GBp at JPMorgan
- Barclays price target raised to 230 GBp from 220 GBp at JPMorgan
- Barclays upgraded to Buy from Reduce at AlphaValue/Baader
- Goldman pulls out of talks to launch co-branded card for T-Mobile US, WSJ says
- Barclays price target lowered to 240 GBp from 250 GBp at Credit Suisse